Physician profile
Tabish Naz
NPI 1245899988
$4,544.62
in general payments reported to CMS, 2019-2025
10 companies · $1,929 in 2025
The $1,929 reported for 2025 was more than what 83% of Sleep Medicine (Family Medicine) providers received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,131 · 2024: $1,485 · 2025: $1,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,550 · Food and Beverage: $1,925 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,549.93 |
| Food and Beverage | $1,924.70 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $3,568.06 | 2023-2025 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $325.04 | 2024-2025 | Lumryz |
| Harmony Biosciences LLC | $256.61 | 2024-2025 | |
| Itamar Medical INC | $185.06 | 2023 | Watchpatone |
| Jazz Pharmaceuticals INC. | $95.72 | 2024 | |
| Zoll Respicardia, INC. | $37.44 | 2025 | Remede System |
| Lilly USA, LLC | $27.72 | 2024 | Mounjaro |
| Glaxosmithkline, LLC. | $18.04 | 2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Cranial Technologies, INC | $17.21 | 2024 | Doc Band |
| Alkermes, INC. | $13.72 | 2024 | Vivitrol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabish Naz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.